TissueGene therapy gets Korean approval for OA

TissueGene Inc. (Rockville, Md.) said Korea approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis (OA) of the knee. Partners Kolon Life Science Inc. (KOSDAQ:102940) and Mundipharma International Ltd. (Dublin, Ireland) will commercialize the therapy in that market. TissueGene expects the product to launch next quarter.

Invossa-K Inj. is a fixed-ratio mixture of non-transduced allogeneic human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1)...